Usher Type News Today

Those with Usher Syndrome -- the leading hereditary cause for simultaneous deafness and blindness, for which there is no treatment -- may have a new reason for hope now that researchers have confirmed the first-ever nonhuman primate model of their disease.

Eli Lilly to buy gene therapy company Akouos for $487 million

Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including ...

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a...

BioPharma

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) Tuesday announced its decision to acquire Akouos, Inc. (AKUS), a developer of viral gene therapies for the treatment of inner ear conditions

Sensorion: A Chardan Top Pick for 2021 Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the US healthcare investment bank Chardan decision to make Sensorion one of its top picks for 2021, calling the company "2021s hidden gem in gene therapy". It raised its target price to €7, following the an...

(2) Regulatory News: Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the companys Board of Directors has approved the procedure for holding an Extraordinary General Meeting behind closed doors ( à huis clos) on Wednesday, March 24, 2021. In accordance with article 4 of ordinance n° 2020-321 of March 25, 2020 as amende...

(2) Key new findings by the Institut Pasteur concerning the gene target GJB2, enables Sensorion to potentially address important hearing loss segments in adults and children GJB2 mutations are the most prevalent cause of congenital deafness; the gene target potentially opens up a pipeline of indications Three initial indications to be targeted: congenital deafness, a progressive form of hearing loss in childhood and early onset of severe presbycusis in adults Webcast planned for Tuesday, Febru...

Half-year report on the Sensorion liquidity contract with Kepler Cheuvreux Regulatory News: Sensorion (FR0012596468 ALSEN) (Paris:ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, issued the half-year report on its liquidity contract with Kepler Chevreux. As of December 31, 2020, the following assets appeared on the liquidity account Sensorion ordinary shares...